Furthermore, combining our metabolic panel with NSE and ProGRP could provide a better diagnosis of SCLC with an improved AUC, indicating the complementarity of our diagnostic panel and the conventional biomarkers. The gene discussed is ENO2; the disease is small cell lung carcinoma.